Press Releases March 31, 2026 08:00 PM

Carlsmed, Inc. To Participate in the 25th Annual Needham Virtual Conference

Carlsmed to Present at 25th Annual Needham Virtual Conference, Showcasing AI-Enabled Spine Surgery Innovations

By Ajmal Hussain
Share
Twitter Reddit Facebook LinkedIn
CARL

Carlsmed, Inc., a medical technology company specializing in AI-driven personalized spine surgery solutions, announced that CEO Mike Cordonnier will present at the 25th Annual Needham Virtual Conference on April 13, 2026. The presentation aims to highlight the company's mission to improve spine surgery outcomes and reduce healthcare costs. A live webcast and subsequent replay will be available for registered participants.

Carlsmed, Inc. To Participate in the 25th Annual Needham Virtual Conference
CARL
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Carlsmed focuses on AI-enabled personalized spine surgery solutions.
  • CEO to present company’s vision and innovations at a major investor conference.
  • The event provides increased visibility to potential investors and partners in the medical technology sector.

CARLSBAD, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced that Mike Cordonnier, CEO and Chairman, will be presenting at the 25th Annual Needham Virtual Conference on April 13, 2026 at 11:45 AM ET.

A live webcast will be available to registered participants. Following the presentation, the webcast replay will be available at https://event.summitcast.com/view/cCMfZsH5ZqrwSNTwfC9JDv/RczDxtnmshQKpi2ivHQcH3

About Carlsmed, Inc.

Carlsmed is a medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond.

Investor Relations
Caroline Corner, PhD
[email protected]

Media
LeAnn Burton
Senior Director Brand Marketing
[email protected]


Risks

  • Market adoption of AI-enabled spine surgery technologies remains uncertain, impacting growth potential.
  • Competition within the medical technology and healthcare innovation sectors could affect market share.
  • Regulatory and reimbursement challenges in healthcare may influence the commercial success of Carlsmed’s solutions.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026